|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Livraghi T, Mäkisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011.PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asghar U and Meyer T: Are there
opportunities for chemotherapy in the treatment of hepatocellular
cancer? J Hepatol. 56:686–695. 2012. View Article : Google Scholar
|
|
6
|
Bartel DP: microRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malan-Müller S, Hemmings SM and Seedat S:
Big effects of small RNAs: A review of microRNAs in anxiety. Mol
Neurobiol. 47:726–739. 2013. View Article : Google Scholar :
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kovalchuk O, Filkowski J, Meservy J,
Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement
of microRNA-451 in resistance of the MCF-7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu K, Liu S, Zhang W, Ji B, Wang Y and
Liu Y: miR-222 regulates sorafenib resistance and enhances
tumorigenicity in hepatocellular carcinoma. Int J oncol.
45:1537–1546. 2014.PubMed/NCBI
|
|
14
|
Tian H, Hou L, Xiong YM, Huang JX, She YJ,
Bi XB and Song XR: miR-218 suppresses tumor growth and enhances the
chemosensitivity of esophageal squamous cell carcinoma to
cisplatin. Oncol Rep. 33:981–989. 2015.
|
|
15
|
Li C, Feng Y, Coukos G and Zhang L:
Therapeutic microRNA strategies in human cancer. AAPS J.
11:747–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Diakos C, Zhong S, Xiao Y, Zhou M,
Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M, Wiencke JK, et
al: TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and
miRNA-320a. Blood. 116:4885–4893. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan H, Jiang Y, Zhang H and Wu Y: miR-320
and miR-494 affect cell cycles of primary murine bronchial
epithelial cells exposed to benzo[a]pyrene. Toxicol In Vitro.
24:928–935. 2010. View Article : Google Scholar
|
|
18
|
Zhao JJ, Yang J, Lin J, Yao N, Zhu Y,
Zheng J, Xu J, Cheng JQ, Lin JY and Ma X: Identification of miRNAs
associated with tumorigenesis of retinoblastoma by miRNA microarray
analysis. Childs Nerv Syst. 25:13–20. 2009. View Article : Google Scholar
|
|
19
|
Asuthkar S, Velpula KK, Nalla AK, Gogineni
VR, Gondi CS and Rao JS: Irradiation-induced angiogenesis is
associated with an MMP-9-miR-494-syndecan-1 regulatory loop in
medulloblastoma cells. Oncogene. 33:1922–1933. 2014. View Article : Google Scholar
|
|
20
|
Romano G, Acunzo M, Garofalo M, Di Leva G,
Cascione L, Zanca C, Bolon B, Condorelli G and Croce CM: miR-494 is
regulated by ERK1/2 and modulates TRAIL-induced apoptosis in
non-small-cell lung cancer through Bim downregulation. Proc Natl
Acad Sci USA. 109:16570–16575. 2012. View Article : Google Scholar
|
|
21
|
Lim L, Balakrishnan A, Huskey N, Jones KD,
Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, et al:
MicroRNA-494 within an oncogenic microRNA megacluster regulates
G1/S transition in liver tumorigenesis through suppression of
mutated in colorectal cancer. Hepatology. 59:202–215. 2014.
View Article : Google Scholar :
|
|
22
|
Liu L, Jiang Y, Zhang H, Greenlee AR and
Han Z: Overexpressed miR-494 down-regulates PTEN gene expression in
cells transformed by
anti-benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Life Sci.
86:192–198. 2010. View Article : Google Scholar
|
|
23
|
Sun HB, Chen X, Ji H, Wu T, Lu HW, Zhang
Y, Li H and Li YM: miR-494 is an independent prognostic factor and
promotes cell migration and invasion in colorectal cancer by
directly targeting PTEN. Int J oncol. 45:2486–2494. 2014.PubMed/NCBI
|
|
24
|
Esquela-Kerscher A and Slack FJ: Oncomirs
-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benetatos L, Hatzimichael E, Londin E,
Vartholomatos G, Loher P, Rigoutsos I and Briasoulis E: The
microRNAs within the DLK1-DIO3 genomic region: Involvement in
disease pathogenesis. Cell Mol Life Sci. 70:795–814. 2013.
View Article : Google Scholar
|
|
26
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: microRNA-494-3p targets CxCR4 to
suppress the proliferation, invasion, and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ohdaira H, Sekiguchi M, Miyata K and
Yoshida K: MicroRNA-494 suppresses cell proliferation and induces
senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012.
View Article : Google Scholar
|
|
30
|
Kim WK, Park M, Kim YK, Tae YK, Yang HK,
Lee JM and Kim H: MicroRNA-494 downregulates KIT and inhibits
gastrointestinal stromal tumor cell proliferation. Clin Cancer Res.
17:7584–7594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Libório-Kimura TN, Jung HM and Chan EK:
miR-494 represses HOXA10 expression and inhibits cell proliferation
in oral cancer. Oral Oncol. 51:151–157. 2015. View Article : Google Scholar
|
|
32
|
Yamanaka S, Campbell NR, An F, Kuo SC,
Potter JJ, Mezey E, Maitra A and Selaru FM: Coordinated effects of
microRNA-494 induce G2/M arrest in human
cholangiocarcinoma. Cell Cycle. 11:2729–2738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou X, Zhu H and Lu J: PTEN and hTERT
gene expression and the correlation with human hepatocellular
carcinoma. Pathol Res Pract. 211:316–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chalhoub N and Baker SJ: PTEN and the
Pi3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar :
|
|
35
|
Wang Y, Liu Y, Du Y, Yin W and Lu J: The
predictive role of phosphatase and tensin homolog (PTEN) loss,
phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway
activation in sensitivity to trastuzumab in HER2-positive breast
cancer: A meta-analysis. Curr Med Res Opin. 29:633–642. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ren Y, Zhou X, Qi Y, Li G, Mei M and Yao
Z: PTEN activation sensitizes breast cancer to PI3-kinase inhibitor
through the β-catenin signaling pathway. Oncol Rep. 28:943–948.
2012.PubMed/NCBI
|
|
37
|
Degraffenried LA, Fulcher L, Friedrichs
WE, Grünwald V, Ray RB and Hidalgo M: Reduced PTEN expression in
breast cancer cells confers susceptibility to inhibitors of the PI3
kinase/Akt pathway. Ann Oncol. 15:1510–1516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun H, Cui C, Xiao F, Wang H, Xu J, Shi X,
Yang Y, Zhang Q, Zheng X, Yang X, Wu C and Wang L: miR-486
regulates metastasis and chemosensitivity in hepatocellular
carcinoma by targeting CLDN10and CITRON. Hepatol Res. Feb
5–2015.Epub ahead of print. View Article : Google Scholar
|
|
39
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224.
2015.PubMed/NCBI
|
|
40
|
Salvi A, Conde I, Abeni E, Arici B, Grossi
I, Specchia C, Portolani N, Barlati S and De Petro G: Effects of
miR-193a and sorafenib on hepatocellular carcinoma cells. Mol
Cancer. 12:1622013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
